Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and ... Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say ...

Bayer is worried about your heart health. | Older millennials, take note: Bayer is worried about your heart health. The drugmaker set out its concerns in an ad for aspirin, showing how people are ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

In its See Your Risks campaign, Bayer takes aim at denial among millennials and Gen Xers when it comes to heart disease. To ...

The optimism is rooted in new launches, Stefan Oelrich, head of Bayer’s pharma division ... we will address right where the sweet spot for us is,” Oelrich said. JPM25: After BridgeBio touts ...

Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused ...

Palo Alto, California Thursday, February 13, 2025, 12:00 Hrs [IST] ...

Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone, and elinzanetant.

For the quarter ended December 31, 2024, the fund returned -8.48% compared to the MSCI World ex USA ... Pharmaceuticals, and Consumer Health segments. The one-month return of Bayer ...

ZURICH (Reuters) - Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an ...

ZURICH (Reuters) - Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an ...